3 Under-the-Radar Stocks to Buy and Hold for a Decade

The article highlights three biotechs with attractive long-term upside, led by Madrigal's 127% YoY Q1 revenue growth to $311.3 million and Axsome's 57% revenue growth to $191.2 million. Madrigal's Rezdiffra treated more than 42,250 patients as of March 31, while Axsome's Auvelity gained an Alzheimer's agitation label expansion and management now sees peak sales of $8 billion. Kailera is earlier stage and riskier, but its phase 3 ribupatide program and planned oral candidate position it for possible upside in the growing obesity market.

Analysis

The setup is less about “which biotech is good” and more about which commercialization curve is still underappreciated. AXSM is the cleanest near-term compounding story: the label expansion materially widens the addressable prescriber base without requiring a new commercial infrastructure, so the market may be underestimating how much incremental revenue can come from the existing sales force over the next 2-3 quarters. That said, the stock likely needs continued prescription acceleration to avoid multiple compression because high-growth biotechs are being valued increasingly on durability rather than just approval optionality.

MDGL is transitioning from pure launch story to competitive-defensibility story. The first-mover advantage is real, but the second-order risk is that every new entrant educates the market and lowers physician inertia, which can slow share gains even if the overall category grows. The key catalyst window is the next 6-18 months: if patient starts and persistency hold while reimbursement broadens, the stock can rerate; if not, the market will start discounting MASH as a multi-winner category rather than a monopolistic one.

KLRA is the highest-beta call option on obesity category breadth. The market tends to overfocus on “GLP-1 vs GLP-1” efficacy, but the more important variable is tolerability plus manufacturing and access at scale; small caps usually fail on one of those before they fail clinically. The contrarian angle is that a successful phase 3 readout may not translate into a large commercial franchise unless the company can prove differentiated dosing, pricing, or formulation economics versus incumbent giants.

Overall, the consensus is too linear on upside and too complacent on execution risk. The best risk/reward is probably in AXSM for momentum plus catalyst support, while MDGL is a hold/add on pullbacks and KLRA is strictly venture-style sizing until phase 3 de-risks.

Key Decisions for Investors

• Long AXSM into the next 2 quarters: best risk/reward on commercial leverage from the new label, with upside if the market starts pricing peak-sales optionality; use a trailing stop on a disappointment in quarterly RX growth.
• Accumulate MDGL on weakness over the next 6-12 months: first-mover advantage still matters, but size modestly because competitive entrants can cap the multiple even if revenue keeps growing.
• Treat KLRA as a small, venture-style position only ahead of phase 3 catalysts: upside is asymmetric if efficacy/discontinuation data differentiate, but the binary risk warrants strict sizing.
• Pair trade: long AXSM / short NVO over 3-6 months if the goal is expressing relative U.S. specialty commercialization strength versus a broader incumbent exposed to category normalization.
• Sell downside protection on MDGL only if you already own the name: use puts or collars into catalyst windows to finance upside while defending against clinical/regulatory volatility.